BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26063766)

  • 1. Inhibition of Glucosylceramide Synthase Sensitizes Head and Neck Cancer to Cisplatin.
    Roh JL; Kim EH; Park JY; Kim JW
    Mol Cancer Ther; 2015 Aug; 14(8):1907-15. PubMed ID: 26063766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
    Roh JL; Park JY; Kim EH; Jang HJ
    Eur J Cancer; 2016 Jan; 52():163-72. PubMed ID: 26687835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition.
    Kim EH; Jang H; Roh JL
    Mol Cancer Ther; 2016 Nov; 15(11):2620-2629. PubMed ID: 27550943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.
    Roh JL; Park JY; Kim EH; Jang HJ; Kwon M
    Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
    Roh JL; Kim EH; Jang HJ; Park JY; Shin D
    Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
    Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
    Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer.
    Kim EH; Jang H; Shin D; Baek SH; Roh JL
    Apoptosis; 2016 Nov; 21(11):1265-1278. PubMed ID: 27544755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
    Roh JL; Kim EH; Jang H; Shin D
    Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
    Shin D; Kim EH; Lee J; Roh JL
    Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hederagenin Induces Apoptosis in Cisplatin-Resistant Head and Neck Cancer Cells by Inhibiting the Nrf2-ARE Antioxidant Pathway.
    Kim EH; Baek S; Shin D; Lee J; Roh JL
    Oxid Med Cell Longev; 2017; 2017():5498908. PubMed ID: 29456786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer.
    Roh JL; Park JY; Kim EH
    Apoptosis; 2014 Nov; 19(11):1594-602. PubMed ID: 25113507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
    Shin D; Kim EH; Lee J; Roh JL
    Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition.
    Roh JL; Kim EH; Jang H; Shin D
    Free Radic Biol Med; 2017 Mar; 104():1-9. PubMed ID: 28057599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GCS overexpression is associated with multidrug resistance of human HCT-8 colon cancer cells.
    Song M; Zang W; Zhang B; Cao J; Yang G
    J Exp Clin Cancer Res; 2012 Mar; 31(1):23. PubMed ID: 22424291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceramide glycosylation potentiates cellular multidrug resistance.
    Liu YY; Han TY; Giuliano AE; Cabot MC
    FASEB J; 2001 Mar; 15(3):719-30. PubMed ID: 11259390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.
    Liu YY; Gupta V; Patwardhan GA; Bhinge K; Zhao Y; Bao J; Mehendale H; Cabot MC; Li YT; Jazwinski SM
    Mol Cancer; 2010 Jun; 9():145. PubMed ID: 20540746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma.
    He C; Sun Z; Hoffman RM; Yang Z; Jiang Y; Wang L; Hao Y
    Anticancer Res; 2019 Apr; 39(4):1711-1718. PubMed ID: 30952710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer.
    Roh JL; Kim EH; Park JY; Kim JW; Kwon M; Lee BH
    Oncotarget; 2014 Oct; 5(19):9227-38. PubMed ID: 25193861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
    Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
    Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma.
    Stefanovic M; Tutusaus A; Martinez-Nieto GA; Bárcena C; de Gregorio E; Moutinho C; Barbero-Camps E; Villanueva A; Colell A; Marí M; García-Ruiz C; Fernandez-Checa JC; Morales A
    Oncotarget; 2016 Feb; 7(7):8253-67. PubMed ID: 26811497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.